Polycystic Kidney Disease Does Not Decrease Alkaline Phosphatase
Polycystic kidney disease (PKD) does not cause a decrease in serum alkaline phosphatase (ALP); rather, ALP levels typically increase as chronic kidney disease (CKD) progresses, and elevated ALP is associated with worse outcomes including mortality and progression to end-stage kidney disease.
The Relationship Between PKD, CKD, and Alkaline Phosphatase
What Happens to ALP in PKD/CKD
In autosomal dominant polycystic kidney disease (ADPKD), patients develop progressive CKD, and as kidney function declines, ALP levels tend to rise, not fall. Multiple lines of evidence demonstrate this:
ALP increases with CKD progression: In a large cohort of 28,678 patients with CKD stages 3-4, higher ALP quartiles were independently associated with increased mortality and progression to end-stage renal disease 1. Each 1-SD increase in ALP (42.7 U/L) was associated with 15% increased risk of ESRD and 16% increased mortality 1.
ALP variability predicts outcomes: Recent data from over 14,000 CKD patients showed that both baseline ALP elevation and greater ALP variability over time were significantly associated with increased all-cause mortality and ESKD risk 2. The highest quartile of ALP showed a 1.47-fold higher mortality risk compared to the lowest 2.
Liver fraction of ALP is particularly elevated: In CKD patients, including those on hemodialysis, the liver fraction of ALP is elevated more than two-fold compared to controls, and this liver ALP fraction independently associates with mortality 3.
Why ALP Increases in CKD/PKD
The elevation of ALP in CKD reflects multiple pathophysiologic processes:
Bone metabolism disturbances: As kidney function declines, mineral and bone disorders develop, with elevated parathyroid hormone driving increased bone ALP 4
Inflammatory milieu: Serum ALP levels associate strongly with elevated C-reactive protein independent of vitamin D levels, suggesting ALP serves as a marker of systemic inflammation in CKD 5
Renal tubular injury: Kidney damage itself may release ALP from injured brush border membranes of renal tubular cells 6
The Exception: Decreased ALP in Specific Conditions
The only scenario where you would see markedly subnormal or low ALP is in fulminant liver failure from Wilson disease, where ALP is characteristically very low (typically <40 IU/L) 7. This is completely unrelated to polycystic kidney disease.
Clinical Implications for PKD Patients
Monitoring Recommendations
For patients with ADPKD:
- Expect ALP to be normal or elevated, particularly as CKD progresses beyond stage 3
- Monitor ALP trends over time: Increasing ALP or high ALP variability signals worse prognosis 2
- Investigate elevated ALP appropriately: While bone and mineral metabolism disorders are common in CKD, also consider cholestatic liver disease (though rare in ADPKD) 8, 9
- In ADPKD with early CKD (G1-2): Bone turnover markers may be reduced, but ALP itself remains normal or slightly elevated 10
Common Pitfall to Avoid
Do not confuse the low bone turnover sometimes seen in early ADPKD 10 with low ALP levels. Bone turnover markers (like PINP and BALP) may be reduced in early ADPKD, but total serum ALP—which includes liver, bone, and intestinal fractions—does not decrease and typically increases as kidney disease progresses.
When to Suspect Other Diagnoses
If you encounter a patient with presumed PKD who has unexpectedly low ALP (<40 IU/L):
- Consider Wilson disease presenting with fulminant hepatic failure, especially if accompanied by Coombs-negative hemolytic anemia, modest aminotransferase elevations, and coagulopathy 7
- Verify the PKD diagnosis is correct
- Rule out laboratory error